First it was Sirna Therapeutics (formerly Ribozyme Pharmaceuticals), then it was CytRx. Now another drug developer, New Zealand-based Genesis Research and Development, has turned to RNAi to fill in its pipeline after its development of other biotechnologies failed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In a commentary at eLife, Brandeis University's Eve Marder calls on researchers to value and pursue truth.

Researchers have developed a way to quickly edit white blood cells, according to the New York Times.

In Science this week: rice gene enables plants to grow quickly in times of flooding, and more.

Education-linked genetic variants could also predict a small portion of a person's social mobility, Newsweek reports.

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research. 

Aug
07
Sponsored by
Qiagen

This webinar will present the results of an evaluation of a web-based variant interpretation software system for clinical next-generation sequencing.